Support the international community to fight counterfeit drugs with digital tools
The development of biotechnology holds tremendous promises for the developing world
We pledge to provide regulatory, advisory and research expertise to improve the quality of your life
Growth Rate Forecast: 4.81%
Biotechnology involves transformative technologies for medicine, environment and agriculture. The use of living systems and organisms to make or develop products has increased dramatically over the recent years.
An increasing demand for biotechnology-based diagnostics and therapeutics solutions such as DNA sequencing, tissue engineering and regeneration, cell-based assay promotes funding to support R&D and new product development endeavours.
2017 was a record year for biotech investments. VC funding for digital health accounted for nearly $4.5 billion which is approximately 109% up in comparison with 2016.
According to our estimates, the world biotechnology market value will cross $2 trillion in 2018 with 67% of manufacturers revenue coming from the sales of biotech and pharmaceutical products.
We expect the global biotech industry to register a stable annual growth of around 4.9% during the next 5 years.
Genome analysis cost has significantly reduced because of the emergence of second and third generation sequencing technologies (NGS). As a whole genome scanning cost falls the personalised medicine grows, a new understanding of the genetic variation of individuals is appeared. Moreover, unidentified vast regions of DNA now are clear and unlocked.
Medical scientists and drug developers have tremendous opportunities to test drugs in the lab as they see how stem cells are able to grow into any of the body’s specialised cells. However, their major goal and perspective is to rise to an era of regenerative medicine where life-altering injuries and deadly diseases are not just treated, but cured.
Commonly, the basic cure for a specific disease is when drugs interact by binding with proteins. Some clinical methods solves this problem by acting directly on genes that are responsible for producing the deleterious protein. For accomplishing this there are number of technologies that introduce a gene through a viral vector, RNAi, antisense or use so-called zinc finger proteins.
MicroRNA is a new way of diagnosing and treating disease. MicroRNAs prevents the translation of messenger RNA into proteins by breaking down of messenger RNA. The absence or presence of specific microRNAs in various cells is held by specific human diseases, including cancer, viral infection, metabolic disorders and inflammatory disease.
Growing prevalence of chronic diseases heightening the demand for new drug development is one of the key factors of segment growth during the next 5-year period. The combination of biotechnology and pharmaceutical results in the development of effective and advanced therapies used to treat many life threatening diseases.
Intelligent and implantable devices serve medicine with monitoring the health of an individual and, in some cases, alert or even respond to changing conditions within the body.
Biotechnology gives good grounds for expecting cheaper and safer vaccines. Alternatively DNA vaccines use a piece of genetic code for a pathogen instead of using a weakened or killed virus use a piece of genetic code for a pathogen. Traditional methods involve using eggs to grow vaccines. DNA vaccines can be made cardinally quicker and production is more bigger and innovative.
Synthetic biology includes a construction of DNA as a basis for building organisms that can perform specific tasks. It is a major part in developing new biofuels that can break the world’s addiction to petroleum. This sphere draws a great attention for its potential in providing cleaner and renewable sources of fuel. Thus it is changing everything from the way drugs are made to the way industrial goods are manufactured.
Systems biology focuses on understanding the interaction between a series of genes and their interactions with proteins. Advances in computing, the falling cost of genetic analysis, and other technological advances made this data-intensive approach possible.
Accelerated breakthroughs in Adoptive T-cell therapies will contribute to the growth of immuno-oncology market during the next 10 years.
Bacteriorhodopsin is a photosensitive protein of purple membranes of Halobacterium salinarum microorganisms living in salt lakes, where the salt concentration is 6 times higher than in the seawater.
Treatment of psoriasis, asthma, conjunctiviti
The RESTET skin regeneration system is the flagship project focused on the research and development of next generation medicines based on bacteriorhodopsin - one of the most promising means of fighting against diseases such as psoriasis, atopic dermatitis, neurodermatitis and acne. RESTET is a unique breakthrough in the field of molecular biocosmetology and has no side effects. The methods of treatment are effective for any age, sex, duration of skin lesions. The unique process of the synthesis of bacteriorhodopsin has been patented in different countries, including Germany, France, China, Iran and South Korea.
Total Supply12 000 000 000 GEN
Hard Cap70 000 000 $
Soft Cap20 000 000 $
Token price0.01 $
Primary Scientific and Medical Research
Ecosystem and Platform Development
Low Level Design Launch
Ecosystem Alpha Version Testing
Smart-Contract Development and Testing. Grant Application Program Launch
Ecosystem Complete Version Launch
Official Public GENEXI Accelerator Report
Further Ecosystem Development and Scaling
More than 20 years of international experience on business and technology in retail and transactional banking, payments and bank cards, retailing, management consulting, IT and venture capital. Holds MSc in Economics from Maastricht University and an executive degree in innovation from the Haas School of Business at UC Berkeley. He is Chief Operating Officer at Qoin, where he focuses on policy, monetary design, legal advice and tokenomics development. Roel is an external advisor to KICKICO and Bancor Network projects.
For certain large token purchases, Genexi is able to use escrow services provided by Blockchain Law Group. Use of escrow is optional and does not apply to regular purchases. Escrow may be available upon request only. A separate escrow agreement is required.
Head of Medical Research
Head of Operations
Head of Strategy
Head of Business Development
Head of Research
Head of HR
Head of Marketing
Head of IT
Technical Support Lead
13 July 2018
GENEXI Announces Launch of Restet Production
01 July 2018
GENEXI Welcomes Oliver Bussmann To Advisory Board
20 June 2018
London Calling | GENEXI Attends BAIConf 2018
03 June 2018
Meet GENEXI’s New Advisors: Richard O’Rourke & Manuel Rimarachin Dias
22 May 2018
Finwise Summit Tokyo 2018 - GENEXI Insight
18 April 2018
World Blockchain Forum — Investments & ICOs — Dubai
25 March 2018
Global Blockchain Summit Sochi 2018 - A word from our CEO
10 March 2018
Blockchain Leadership Summit | March 9th | Zurich, Switzerland
07 February 2018
GENEXI at Blockchain Economic Forum 2018 in Singapore
14 January 2018
GENEXI - The Finwise Summit Macau 2018
GENEXI Biotech Accelerator has announced the launch of production of their first granted project - RESTET, a skin regeneration system based on the retinal protein bacteriorhodopsin. With the help of grant funds received through GENEXI, the RESTET team was able to build a world-class research lab where they apply their technical know-how to obtain bacteriorhodopsin and produce the RESTET skin regeneration product line. According to GENEXI CEO Aleksei Zheliaskov, RESTET is a unique breakthrough in the field of microbiology and biotechnology, which will become one of the most effective remedies for treatment of skin conditions such as psoriasis, skin dermatitis and acne.
GENEXI Welcomes Oliver Bussmann To Advisory Board June has been another busy and rewarding month for GENEXI with the appointment of new advisors joining GENEXI Foundation. Please welcome a globally recognized technology thought-leader and driver of large-scale transformation at multinational organizations — Oliver Bussmann. The Founder and CEO of Bussmann Advisory AG, Oliver advises enterprises and startups looking to stay ahead of the digital disruption curve. His strengths lie in bringing people together throughout an organization to reach agreement on a desired future state…
Blockchain Alternative Investment Conference and Exhibition, one of London’s best and most central conference venues, took place on 18–19 June at 8 Northumberland. BAIConf proved to be a resounding success in terms of bringing together the leading fund managers in cryptocurrencies, CEOs of successful ICOs from 2017 and 2018, institutions and private investors responsible for over US$750 billion of assets under management. Global institutional investors conclude for a reason that Bitcoin and other cryptocurrencies are an emerging asset class with real challenges to achieving their full potential…
Often businesses require assistance as they make crucial decisions that affect their direction. Experienced advisors can bring the insight business owners need. June 2018, GENEXI is proud to announce new advisors joining the team: Richard O'Rourke and Manuel Rimarachin Dias. GENEXI’s culture is a standout in the world of business and marketing planning, rewarding forward thinking and creativity. Our advisors are our greatest success – we say it often and with good reason. The company instils confidence in our employees and their external teammates, always inspiring one another to find a way forward and master their motivation. We foster a culture of innovation and leadership bringing in the right people to continue develop those values further.
2018 FINWISE Tokyo was held in Tokyo Japan on May 21-22. FINWISE Summit is one of the most influential blockchain events in the world which aims to strengthen the communication among blockchain- related practitioners and encourage the development of global financial technologies. GENEXI Ecosystem Developer Dennis Sarkar was invited as a speaker to announce GENEXI blockchain platform and fundraising campaign that promotes the culture of innovations, as well as embedding the blockchain into biotechnology.
The World Blockchain Forum, Investment & ICOs was held on 16 -17 April, 2018 in Dubai. Major market players joined the leaders of several countries, economic pioneers and enterprising investors hailing from all corners of the world in discussing the future of the financial world. According to GENEXI co-founder and CEO Alexey Zhelyaskov, one of the conference's primary objectives was to understand the strategic tasks of blockchain globalization within the context of rapidly changing economic conditions.
Sochi played host to the Global Blockchain Summit 2018, an international event dedicated to blockchain technology and cryptocurrencies, on 24 March. The program included reports on the following set of pressing issues: the use of blockchain and its future, ICOs, altcoin prospects in 2018 and infrastructural challenges. GENEXI co-founder and CEO Alexey Zhelyaskov delivered a speech on the integration of blockchain and the real sector of economy.
The Blockchain Leadership Summit took place on 9 March, 2018 in Zurich, Switzerland. It is widely regarded as one of the main conferences for experts and visionaries of the blockchain industry. Experts from the real sector, pioneers of the digital economy, investment bankers and officials from Switzerland, Liechtenstein, Kazakhstan, and Russia were among the attendees.
GENEXI co-founder and CEO Alexey Zhelyaskov attended the Blockchain Economic Forum, held on 4-6 February, 2018 in Singapore. The Blockchain Economic Forum accentuated the growing influence of the crypto economy on global economic processes and facilitated a productive dialogue on the most crucial topics. The presence of Vincente Fox, the former President of Mexico, should be noted.
The Finwise Summit was held on 12-13 January, 2018 in Macau. It was aimed at encouraging interaction among the fintech industry participants and fostering further developments in this field. Over 3000 guests, hundreds of investment and fintech companies and roughly 60 blockchain projects attended the summit. UBS and a number of large Chinese banks were listed as major partners.
We will contact you soon